HIV/AIDS situation in Serbia GORDANA J

Slides:

Advertisements

Similar presentations

Adherence in TLC+: The Sticky Wicket Michael S. Saag, MD Center for AIDS Research University of Alabama at Birmingham USA.

Advertisements

Paediatric HIV: update EACS Advanced HIV course Montpellier, 3-5 th Sept 2008 Carlo Giaquinto Department of Paediatrics, Padova, Italy.

Hopital Pitié Salpérière

1 HIV/AIDS Scenario INDIA Dr Milind Kulkarni Dr DSA Karthickeyan.

Management of ARV 6th Advanced HIV Course, Montpellier, September 3-5, 2008 Jürgen Rockstroh, Department of Medicine I, University of Bonn, Germany.

Management of ART in Albania : From the European Guidelines to the real practice. Arjan Harxhi MD, MSc, PhD University Hospital Center of Tirana Mother.

HIV-infection in Russia Alexander Panteleev Head of the HIV/TB department City TB Hospital # 2, St-Petersburg, Russia.

HIV Situation in India Dr Sunil Gaikwad.

A brief overview of ART services at QECH, Malawi Kudzala Aub. MMEDsc. Student Sr. Lead ART Clinician/ HIV Medicine Registrar.

Key1 ARV Treatment Guidelines for a Public Health Approach Product Selection for HIV Treatment Vincent Habiyambere January 2006.

World Health Organization Surveys of Transmitted and Acquired HIV Drug Resistance in Resource Limited Settings CROI 2011 S Bertagnolio*, K Kelley*, A Saadani.

ART in HIV-Infected Patients with TB: Research Priorities Group II Facilitator: David Cohn Rapporteur: Soumya Swaminathan.

Harmonization of donor reporting requirements for antiretrovirals and related drugs Presented at the WHO meeting, Geneva ( October 2005) Oteba Olowo.

Accessing to ARV in HIV/AIDS care and treatment programme in Vietnam Accessing to ARV in HIV/AIDS care and treatment programme in Vietnam Dr.Nguyen Van.

How Universal will Universal Access be in Europe by 2010? Eddy Beck Evaluation Department UNAIDS, Geneva

Thailands experience with using program data to improve PMTCT strategies and outcomes. Sarawut Boonsuk, MD. MPH Chief of MCH, Bureau of Health Promotion.

List of figure titles 1.Estimated percentage of people aged 20 years or older with diagnosed and undiagnosed diabetes, by age group, United States, 2005–2008.

Clinical Care: 2010 Institute of Medicine Committee on HIV Screening and Access to Care Michael Saag, MD, FIDSA University of Alabama, Birmingham Director,

ARV failure and resistance for the paediatrician

TOWARDS UNIVERSAL ACCESS

WHO Guidelines and future perspectives for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.

Name ____________________ Date ___________ Period ____.

ARV overview and toxicity Dr Francois Venter Reproductive Health Research Unit University of the Witwatersrand.

HIV and Aging Kathleen K Casey, MD Director, AIDS Ambulatory Care Center Jersey Shore University Medical Center.

Slide #1 HIV Entry Inhibitors Trip Gulick, MD, MPH Director, Cornell HIV Clinical Trials Unit Associate Professor of Medicine Weill Medical College of.

Evaluation of three 2 nd Line Antiretroviral regimens in Africa (Dakar, Yaounde) « 2 LADY » ANRS project.

VIREAD (Tenofovir DF) Update. Viread Update  Pharmacokinetics  Safety & Tolerability  Efficacy  Virology.

Pre Test !!!!!!. How many classes of HIV meds are currently available?

Fabio Mesquita, MD, PhD Director of the Brazilian Ministry of Health’s HIV/AIDS and Viral Hepatitis Department July 20th, 2014 Evidence.

Principles of HIV Therapy Simple is Better! Adeel A. Butt, MD Assistant Professor of Medicine and Infectious Diseases University of Pittsburgh Director,

HIV (+) pregnant woman Prophylaxis of mother-to-child transmission Manegemant of a woman, who needs ARV medication.

ANTIRETROVIRAL RESISTANCE Jennifer Fulcher, MD, PhD.

Adverse Reactions & Antiretroviral Therapy Kirsten B. Balano, PharmD October 26, 2002.

HIV/ AIDS Answers to your questions. What is HIV HIV- Human Immunodeficiency Virus HIV- Human Immunodeficiency Virus The virus attacks the T-Cells in.

Application of Patients’ Rights in Cross-Border Health Care Regional meeting and workshop February 2009 Budapest ŠKUC – Magnus, SLOVENIA Miran Šolinc.

Improving Adherence With Simplified HAART Regimens Improving Clinical Outcomes in HIV Patients.

Accessibility of medicinal products before marketing authorisation : The French experience C. Bélorgey Division on Evaluation of medicinal products of.

Global HIV Resistance: The Implications of Transmission

Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents Roger Bedimo, MD; Song Zhang, PhD; Henning.

Failure Therapy VIRAL RESITANCE ADHERENCE!!!!!!!!!!! DRUG INTERACTION.

When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.

1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.

1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.

1 Research Advances in HIV Care Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine.

Intellectual Property Law FDA Thailand Health Insurance in Thailand.

Current Concepts in HIV/AIDS A Pharmacy Perspective Carol Schneiderman, Pharm D Clinical Pharmacist, University of Arizona.

Key1 ARV Treatment Guidelines for a Public Health Approach Product Selection for HIV Treatment Vincent Habiyambere February 2006.

Current and Future Trends in HIV Therapy Hail M. Al-Abdely Consultant, Infectious Diseases.

1 HIV Drugs, Updates, & the Hope for Entry Inhibitors Kent Williams Doctor of Pharmacy Candidate 2011 Wingate University School of Pharmacy Saturday, February.

Dr Ihor Perehinets MD, MPH National Technical Officer WHO CO in Ukraine Pharmacovigilance (PV) in HIV treatment in Ukraine: Situation Analysis Dar es Salaam.

Washington D.C., USA, July 2012www.aids2012.org Changing Patterns of NRTI and PI Resistance Mutations Between 2006 and 2011 in ART experienced SA.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Treatment-Experienced Patients in Resource- Limited Settings Susan M. Graham Assistant Professor, Medicine.

11 INTRODUCTION TO ANTIRETROVIRAL THERAPY (ART) IN CHILDREN: INITIATION AND MONITORING HAIVN Harvard Medical School AIDS Initiatives in Vietnam.

Long-Term Changes in Lipids and Glucose/Insulin among HIV-Infected Antiretroviral Naïve Persons Randomized to PI vs. NNRTI vs. PI+NNRTI-based strategies:

HIV in Brazil Daniela Zilio Larentis Infectious Disease Resident at HCPA.

Retrovirus HIV (humans) Animal viruses resulting in cancer / AIDS 15-39%

Human Immunodeficiency Virus – HIV and the correctional system.

WHO 2013 Consultative Meeting Tawanna Hotel October 15, 2013.

Switch to PI/r monotherapy

Justine Mirembe MD, MPH ICASA, 5th December 2011

ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:

Answers to your questions

Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses

Giới thiệu về điều trị ARV

Results of round 1 of the Delphi survey

Forecasting for ARVs medicines

ART Use in Selected PEPFAR Countries Forecasting for ARVs to 2010 November 7-8, 2005 Rational Pharmaceutical Management Plus.

Antiretroviral therapy and its complications

Presentation transcript:

HIV/AIDS situation in Serbia GORDANA J HIV/AIDS situation in Serbia GORDANA J. DRAGOVIĆ LUKIĆ, MD, PhD Department of Clinical Pharmacology, Pharmacology and Toxicology; School of Medicine, University of Belgrade, Belgrade, Serbia

IT BiH MN HR H RO BG MK AL GR TR SLO SERBIA A Belgrade, Serbia

Current Epidemiological HIV/AIDS Situation in Serbia HIV prevalence (case registration by the end of June 2010.): 2414 cumulative 1472 AIDS 962 died 1382 PLWHA HIV testing prevalence very low: 1.5/1000 (6 -11x higher numbers - “real life”) Since 1987 mandatory HIV testing

Current Epidemiological HIV/AIDS Situation in Serbia Of all HIV/AIDS cases in 2010: 47% IDUs 62% MSM 31% heterosexual HAART introduced by the public health insurance system in 1997.

Currently available antiretroviral drug in Serbia NRTI AZT, ZDV Zidosan® ddI Videx EC® d4T Zerit® 3TC Epivir® ABC Ziagen® 3TC/ZDV Combivir® TDF/FTC Truvada® ABC/3TC Kivexa® NNRTI EFV Stocrin® NVP Viramune® ETV Intelence®

Currently available antiretroviral drug in Serbia PI LPV/r Aluvia® IDV Crixivan® RTV Norvir® SQV Invirase® FPV Telzir® DRV Prezista® II RLG Isentress® R5 MVC Celsentri® IF T-20 Fuzeon®

HIV/AIDS Centers in Serbia Beograd (890 pts) Novi Sad (76 pts) Nis (54 pts) Kragujevac (4 pts) Novi Sad Beograd Kragujevac Nis

Previous responses to HIV/AIDS Challenge Main achievements in the last few years: 2002 National Commission to fight HIV/AIDS 2005-2010 National Strategy for the fight against HIV/AIDS in Serbia 2006 National Office for HIV/AIDS 2010-2015 National Strategy for the fight against HIV/AIDS in Serbia

Previous responses to HIV/AIDS Challenge 2008 Candle light memorial day Main achievements in the last few years: 2007 National Guideline for Clinical Management and Treatment of HIV Infection 2008 Candle light memorial day 2009 Antidiscrimination law May 2009 New EACS Guidelines version addopted as a National Guidelines